CN1774500B - 用于瞬时或稳定表达外源分子的表达盒和载体 - Google Patents

用于瞬时或稳定表达外源分子的表达盒和载体 Download PDF

Info

Publication number
CN1774500B
CN1774500B CN2004800101473A CN200480010147A CN1774500B CN 1774500 B CN1774500 B CN 1774500B CN 2004800101473 A CN2004800101473 A CN 2004800101473A CN 200480010147 A CN200480010147 A CN 200480010147A CN 1774500 B CN1774500 B CN 1774500B
Authority
CN
China
Prior art keywords
expression cassette
sequence
seq
polynucleotide
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2004800101473A
Other languages
English (en)
Chinese (zh)
Other versions
CN1774500A (zh
Inventor
威廉·P·西斯克
霍利·普伦蒂斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN1774500A publication Critical patent/CN1774500A/zh
Application granted granted Critical
Publication of CN1774500B publication Critical patent/CN1774500B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Tents Or Canopies (AREA)
  • Paints Or Removers (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN2004800101473A 2003-02-14 2004-02-13 用于瞬时或稳定表达外源分子的表达盒和载体 Expired - Lifetime CN1774500B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44817903P 2003-02-14 2003-02-14
US60/448,179 2003-02-14
PCT/US2004/004407 WO2004074439A2 (en) 2003-02-14 2004-02-13 An expression cassette and vector for transient or stable expression of exogenous molecules

Publications (2)

Publication Number Publication Date
CN1774500A CN1774500A (zh) 2006-05-17
CN1774500B true CN1774500B (zh) 2011-03-02

Family

ID=32908549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800101473A Expired - Lifetime CN1774500B (zh) 2003-02-14 2004-02-13 用于瞬时或稳定表达外源分子的表达盒和载体

Country Status (21)

Country Link
US (2) US7494805B2 (enExample)
EP (1) EP1594955B1 (enExample)
JP (2) JP2006517802A (enExample)
KR (1) KR20050101554A (enExample)
CN (1) CN1774500B (enExample)
AT (1) ATE553185T1 (enExample)
AU (1) AU2004213797B2 (enExample)
BR (1) BRPI0407487A (enExample)
CA (1) CA2515481A1 (enExample)
DK (1) DK1594955T3 (enExample)
EA (2) EA200700469A1 (enExample)
ES (1) ES2384973T3 (enExample)
IL (1) IL170178A (enExample)
IS (1) IS7974A (enExample)
MX (1) MXPA05008523A (enExample)
NO (1) NO20054202L (enExample)
NZ (1) NZ542316A (enExample)
PL (1) PL378110A1 (enExample)
RS (1) RS20050614A (enExample)
WO (1) WO2004074439A2 (enExample)
ZA (1) ZA200506413B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700469A1 (ru) * 2003-02-14 2008-10-30 Байоджен Айдек Ма Инк. Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул
ATE542793T1 (de) 2003-09-19 2012-02-15 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
RS20060266A (sr) * 2003-10-14 2008-09-29 Biogen Idec Ma Inc., Flp posredovana rekombinacija
BRPI0508862A (pt) * 2004-03-15 2007-09-04 Biogen Idec Inc métodos e construtos para expressar multìmeros de polipeptìdios em células eucarióticas utilizando junção alternativa
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
UY30288A1 (es) 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
US20080166766A1 (en) * 2006-10-18 2008-07-10 The Scripps Research Institute Genetic incorporation of unnatural amino acids into proteins in mammalian cells
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
WO2011084659A1 (en) * 2009-12-21 2011-07-14 Sanofi-Aventis Transgenic non-human animal and uses thereof
UY33126A (es) * 2009-12-21 2011-07-29 Sanofi Sa Animal transgénico no humano y sus usos
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9816102B2 (en) 2012-09-13 2017-11-14 Indiana University Research And Technology Corporation Compositions and systems for conferring disease resistance in plants and methods of use thereof
ES2780398T3 (es) 2012-12-10 2020-08-25 Biogen Ma Inc Anticuerpo anti-antígeno 2 de células dendríticas sanguíneas y uso de los mismos
WO2014162318A2 (en) * 2013-03-30 2014-10-09 Usha Biotech Limited Methods and constructs for expressing biologically active proteins in mammalian cells
WO2015162930A1 (ja) * 2014-04-24 2015-10-29 一般社団法人 医療産業イノベーション機構 タンパク質発現を向上させる方法およびタンパク質発現用組成物
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US11415263B2 (en) * 2020-03-20 2022-08-16 Edwards Vacuum Llc Conversion kit for a support frame, a support frame and an integrated vacuum system mounted in a support frame

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194176B1 (en) * 1996-01-19 2001-02-27 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
WO2001029208A1 (en) * 1999-10-16 2001-04-26 Artemis Pharmaceuticals Gmbh Conditional gene trapping construct for the disruption of genes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA2121798C (en) 1991-10-25 2007-07-24 Richard J. Armitage Novel cytokine
ATE229076T1 (de) 1992-04-02 2002-12-15 Sembiosys Genetics Inc Cis elemente des ölkörperproteins als regulationische signale
CA2223103A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
CA2222914C (en) 1995-06-07 2002-04-02 Immunex Corporation Novel cd40l mutein
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
WO1997040165A1 (en) * 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
CA2297375A1 (en) * 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
EP1047774A1 (en) * 1998-01-16 2000-11-02 California Pacific Medical Center Research Institute Methods and compositions for gene delivery
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
ES2326893T3 (es) * 1998-05-27 2009-10-21 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para administracion potenciada por conveccion.
WO2001094599A1 (en) 2000-06-07 2001-12-13 Smittskyddsinstitutet Gene expression cassette and its use
WO2002002765A2 (en) 2000-07-05 2002-01-10 Transgene S.A. Chimeric promoters for controlling expression in smooth muscle cells
JP2002233374A (ja) * 2001-02-06 2002-08-20 Japan Science & Technology Corp 遺伝子導入及び／又は遺伝子欠損非ヒト動物作製用ベクター
DE10133407A1 (de) 2001-07-13 2003-01-23 Basf Ag Expressionskassetten zur transgenen Expression von Nukleinsäuren
US20030235823A1 (en) * 2002-06-24 2003-12-25 The University Of Alabama Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation
EA200700469A1 (ru) 2003-02-14 2008-10-30 Байоджен Айдек Ма Инк. Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194176B1 (en) * 1996-01-19 2001-02-27 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
WO2001029208A1 (en) * 1999-10-16 2001-04-26 Artemis Pharmaceuticals Gmbh Conditional gene trapping construct for the disruption of genes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C.B. BREWER.Cytomegalovirus Plasmid Vectors for Permanent Lines ofPolarised Epithelial cell.METHODS IN CELL BIOLOGY 43.1994,(43),233-245.
C.B. BREWER.Cytomegalovirus Plasmid Vectors for Permanent Lines ofPolarised Epithelial cell.METHODS IN CELL BIOLOGY 43.1994,(43),233-245. *
D. R. THOMSEN.PROMOTER REGULATORY REGION OF THE MAJORIMMEDIATE EARLY GENE OF HUMANCYTOMEGALOVIRUS.PROC. NATL. ACAD. SCI 81.1984,(81),659-663.
D. R. THOMSEN.PROMOTER REGULATORY REGION OF THE MAJORIMMEDIATE EARLY GENE OF HUMANCYTOMEGALOVIRUS.PROC. NATL. ACAD. SCI 81.1984,(81),659-663. *

Also Published As

Publication number Publication date
PL378110A1 (pl) 2006-03-06
JP2010213718A (ja) 2010-09-30
WO2004074439A9 (en) 2004-12-23
AU2004213797B2 (en) 2009-09-17
US20100158879A1 (en) 2010-06-24
KR20050101554A (ko) 2005-10-24
US20060141625A1 (en) 2006-06-29
DK1594955T3 (da) 2012-06-25
RS20050614A (sr) 2007-12-31
AU2004213797A1 (en) 2004-09-02
ES2384973T3 (es) 2012-07-16
HK1084690A1 (en) 2006-08-04
IS7974A (is) 2005-08-11
IL170178A (en) 2011-12-29
MXPA05008523A (es) 2005-10-20
CN1774500A (zh) 2006-05-17
EP1594955B1 (en) 2012-04-11
US7494805B2 (en) 2009-02-24
WO2004074439A2 (en) 2004-09-02
CA2515481A1 (en) 2004-09-02
EA008439B1 (ru) 2007-06-29
EA200501296A1 (ru) 2006-04-28
WO2004074439A3 (en) 2004-10-28
BRPI0407487A (pt) 2006-02-14
ZA200506413B (en) 2006-04-26
EA200700469A1 (ru) 2008-10-30
NO20054202L (no) 2005-11-11
EP1594955A2 (en) 2005-11-16
NO20054202D0 (no) 2005-09-09
JP2006517802A (ja) 2006-08-03
EP1594955A4 (en) 2006-07-19
NZ542316A (en) 2006-04-28
ATE553185T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
CN1774500B (zh) 用于瞬时或稳定表达外源分子的表达盒和载体
AU2015263150B2 (en) Lentiviral vectors
US9163219B2 (en) Single expression vector for generation of a virus with a segmented genome
DE60018171T2 (de) Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
CN112552380B (zh) 一种SARS-CoV-2病毒的免疫原及其应用
CN106520830B (zh) 利用CRISPR/Cas9对线粒体基因组进行靶向编辑的方法
JP2006517802A5 (enExample)
CN110904155B (zh) 一种碱基编辑器及其制备方法和应用
CN101001951B (zh) 分离转录终止序列的方法
AU2024217163A1 (en) Transposase, transposon, transposon system, and use thereof
CN120210288B (zh) 一种D/Yama2019遗传进化谱系丁型流感病毒反向遗传操作系统
CN113583978A (zh) 3种重组腺病毒以及SARS-CoV-2 Spike蛋白的RBD以及它们的应用
AU2006297112B2 (en) Regulatable fusion promoters
CN107090473A (zh) 抗菌肽pr39和pg1共表达载体和转pr39和pg1基因小鼠制备方法
US20240082327A1 (en) Retroviral vectors
EA010059B1 (ru) Flp-опосредованная рекомбинация
CN109929864A (zh) 核苷酸序列tWPRE及其基因表达载体和应用
NO845186L (no) Vektorsystem for innfoering av heterolog dna i eykaryotiske celler.
HK1122837A (en) Treatment of disease using an improved regulated expression system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: BIOGEN MA INC.

Free format text: FORMER NAME: BIOGEN IDEC MA

CP01 Change in the name or title of a patent holder

Address after: Massachusetts, USA

Patentee after: BIOGEN MA Inc.

Address before: Massachusetts, USA

Patentee before: Biogen Idec MA Inc.

CX01 Expiry of patent term

Granted publication date: 20110302

CX01 Expiry of patent term